The genomic landscape of breast cancer and its interaction with host immunity

Breast

Volumn 29, Issue , 2016, Pages 241-250

  Luen, Stephen ^a   Virassamy, Balaji ^a   Savas, Peter ^a   Salgado, Roberto ^b   Loi, Sherene ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Genomics; Immunity; Immunotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ATEZOLIZUMAB; CD134 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADJUVANT THERAPY; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CLONAL EVOLUTION; GENOMIC INSTABILITY; GENOMICS; HUMAN; IMMUNE EVASION; IMMUNOGENICITY; IMMUNOSURVEILLANCE; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; LYMPHOCYTIC INFILTRATION; METASTATIC BREAST CANCER; MISMATCH REPAIR; MUTATIONAL LOAD; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; SOMATIC MUTATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; BREAST TUMOR; FEMALE; GENETICS; IMMUNOLOGY; TUMOR ESCAPE;

BREAST NEOPLASMS; FEMALE; GENOMICS; HUMANS; PRECISION MEDICINE; TUMOR ESCAPE;

EID: 84989336812     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2016.07.015     Document Type: Article

References (117)

1. [1] Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100:1 (2000), 57–70.
2. [2] Collins, F.S., Morgan, M., Patrinos, A., The human genome project: lessons from large-scale biology. Science 300:5617 (2003), 286–290.
3. [3] Cancer Genome Atlas, N., Comprehensive molecular portraits of human breast tumours. Nature 490:7418 (2012), 61–70.
4. [4] Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:7403 (2012), 346–352.
5. [5] Stephens, P.J., Tarpey, P.S., Davies, H., Van Loo, P., Greenman, C., Wedge, D.C., et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486:7403 (2012), 400–404.
6. [6] Shah, S.P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486:7403 (2012), 395–399.
7. [7] Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:6024 (2011), 1565–1570.
8. [8] Kroemer, G., Senovilla, L., Galluzzi, L., Andre, F., Zitvogel, L., Natural and therapy-induced immunosurveillance in breast cancer. Nat Med 21:10 (2015), 1128–1138.
9. [9] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
10. [10] Vogelstein, B., Kinzler, K.W., The path to cancer –three strikes and you're out. N Engl J Med 373:20 (2015), 1895–1898.
11. [11] Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., et al. Mutational landscape and significance across 12 major cancer types. Nature 502:7471 (2013), 333–339.
12. [12] Pon, J.R., Marra, M.A., Driver and passenger mutations in cancer. Annu Rev Pathol 10 (2015), 25–50.
13. [13] Haricharan, S., Bainbridge, M.N., Scheet, P., Brown, P.H., Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. Breast Cancer Res Treat 146:1 (2014), 211–220.
14. [14] Yang, S.X., Polley, E., Lipkowitz, S., New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev 45 (2016), 87–96.
15. [15] Ciriello, G., Gatza, M.L., Beck, A.H., Wilkerson, M.D., Rhie, S.K., Pastore, A., et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:2 (2015), 506–519.
16. [16] Desmedt, C., Zoppoli, G., Gundem, G., Pruneri, G., Larsimont, D., Fornili, M., et al. Genomic characterization of primary invasive lobular breast cancer. J Clin Oncol 34:16 (2016), 1872–1881.
17. [17] Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30:6 (2012), 587–592.
18. [18] Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., et al. Tumour evolution inferred by single-cell sequencing. Nature 472:7341 (2011), 90–94.
19. [19] Tang, M.H., Dahlgren, M., Brueffer, C., Tjitrowirjo, T., Winter, C., Chen, Y., et al. Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing. Oncotarget 6:35 (2015), 37169–37184.
20. [20] Moelans, C.B., van der Groep, P., Hoefnagel, L.D., van de Vijver, M.J., Wesseling, P., Wesseling, J., et al. Genomic evolution from primary breast carcinoma to distant metastasis: few copy number changes of breast cancer related genes. Cancer Lett 344:1 (2014), 138–146.
21. [21] Meric-Bernstam, F., Frampton, G.M., Ferrer-Lozano, J., Yelensky, R., Perez-Fidalgo, J.A., Wang, Y., et al. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther 13:5 (2014), 1382–1389.
22. [22] Shah, S.P., Morin, R.D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461:7265 (2009), 809–813.
23. [23] Brastianos, P.K., Carter, S.L., Santagata, S., Cahill, D.P., Taylor-Weiner, A., Jones, R.T., et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5:11 (2015), 1164–1177.
24. [24] Andre, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 15:3 (2014), 267–274.
25. [25] Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., et al. Precision medicine for metastatic breast cancer–limitations and solutions. Nat Rev Clin Oncol 12:12 (2015), 693–704.
26. [26] Massard, C., O3.7 * enriching phase I trials with molecular alterations: interim analysis of 708 patients enrolled in the MOSCATO 01. Ann Oncol, 26(suppl. 2), 2015, ii4.
27. [27] Arnedos, M., Filleron, T., Dieci, M.V., Adam, J., Robbins, P.B., Loi, S., et al. 351OGENOMIC and immune characterization of metastatic breast cancer (MBC): and ancillary study of the SAFIR01 & MOSCATO trials. Ann Oncol, 25(suppl. 4), 2014, iv116.
28. [28] Nik-Zainal, S., Van Loo, P., Wedge, D.C., Alexandrov, L.B., Greenman, C.D., Lau, K.W., et al. The life history of 21 breast cancers. Cell 149:5 (2012), 994–1007.
29. [29] Yates, L.R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo, P., et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 21:7 (2015), 751–759.
30. [30] Desmedt, C., Fumagalli, D., Pietri, E., Zoppoli, G., Brown, D., Nik-Zainal, S., et al. Uncovering the genomic heterogeneity of multifocal breast cancer. J Pathol 236:4 (2015), 457–466.
31. [31] Wang, Y., Waters, J., Leung, M.L., Unruh, A., Roh, W., Shi, X., et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512:7513 (2014), 155–160.
32. [32] Eirew, P., Steif, A., Khattra, J., Ha, G., Yap, D., Farahani, H., et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518:7539 (2015), 422–426.
33. [33] Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., Schreiber, R.D., Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:11 (2002), 991–998.
34. [34] Mittal, D., Gubin, M.M., Schreiber, R.D., Smyth, M.J., New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol 27 (2014), 16–25.
35. [35] Zitvogel, L., Tesniere, A., Kroemer, G., Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:10 (2006), 715–727.
36. [36] Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P.K., Smyth, M.J., et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol 13:4 (2016), 228–241.
37. [37] Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:7 (2013), 860–867.
38. [38] Adams, S., Gray, R.J., Demaria, S., Goldstein, L., Perez, E.A., Shulman, L.N., et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:27 (2014), 2959–2966.
39. [39] Dieci, M.V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 25:3 (2014), 611–618.
40. [40] Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:8 (2014), 1544–1550.
41. [41] Loi, S., Drubay, D., Adams, S., Francis, P.A., Joensuu, H., Dieci, M.V., et al. Abstract S1-03: pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy. Cancer Res, 76(4 Suppl.), 2016, S1-03.
42. [42] Salgado, R., Denkert, C., Campbell, C., Savas, P., Nuciforo, P., Aura, C., et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol 1:4 (2015), 448–454.
43. [43] West, N.R., Milne, K., Truong, P.T., Macpherson, N., Nelson, B.H., Watson, P.H., Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res, 13(6), 2011, R126.
44. [44] Denkert, C., Loibl, S., Noske, A., Roller, M., Muller, B.M., Komor, M., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:1 (2010), 105–113.
45. [45] Denkert, C., von Minckwitz, G., Brase, J.C., Sinn, B.V., Gade, S., Kronenwett, R., et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 33:9 (2015), 983–991.
46. [46] Issa-Nummer, Y., Darb-Esfahani, S., Loibl, S., Kunz, G., Nekljudova, V., Schrader, I., et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer–a substudy of the neoadjuvant GeparQuinto trial. PLoS One, 8(12), 2013, e79775.
47. [47] Ali, H.R., Provenzano, E., Dawson, S.J., Blows, F.M., Liu, B., Shah, M., et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 25:8 (2014), 1536–1543.
48. [48] Dieci, M.V., Mathieu, M.C., Guarneri, V., Conte, P., Delaloge, S., Andre, F., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol 26:8 (2015), 1698–1704.
49. [49] Lim, E., Wu, D., Pal, B., Bouras, T., Asselin-Labat, M.L., Vaillant, F., et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res, 12(2), 2010, R21.
50. [50] Dieci, M.V., Griguolo, G., Miglietta, F., Guarneri, V., The immune system and hormone-receptor positive breast cancer: is it really a dead end?. Cancer Treat Rev 46 (2016), 9–19.
51. [51] Nalbandian, G., Paharkova-Vatchkova, V., Mao, A., Nale, S., Kovats, S., The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol 175:4 (2005), 2666–2675.
52. [52] Svensson, S., Abrahamsson, A., Rodriguez, G.V., Olsson, A.K., Jensen, L., Cao, Y., et al. CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancer. Clin Cancer Res 21:16 (2015), 3794–3805.
53. [53] Joffroy, C.M., Buck, M.B., Stope, M.B., Popp, S.L., Pfizenmaier, K., Knabbe, C., Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res 70:4 (2010), 1314–1322.
54. [54] Chan, M.S., Wang, L., Felizola, S.J., Ueno, T., Toi, M., Loo, W., et al. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients–an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. Int J Biol Markers 27:4 (2012), e295–e304.
55. [55] Generali, D., Bates, G., Berruti, A., Brizzi, M.P., Campo, L., Bonardi, S., et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 15:3 (2009), 1046–1051.
56. [56] Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:2 (2015), 259–271.
57. [57] Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L., Kroemer, G., Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28:6 (2015), 690–714.
58. [58] Dadmarz, R., Sgagias, M.K., Rosenberg, S.A., Schwartzentruber, D.J., CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol Immunother 40:1 (1995), 1–9.
59. [59] Matsushita, H., Vesely, M.D., Koboldt, D.C., Rickert, C.G., Uppaluri, R., Magrini, V.J., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:7385 (2012), 400–404.
60. [60] Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:1–2 (2015), 48–61.
61. [61] Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., et al. Signatures of mutational processes in human cancer. Nature 500:7463 (2013), 415–421.
62. [62] Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339:6127 (2013), 1546–1558.
63. [63] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
64. [64] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
65. [65] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
66. [66] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:17 (2015), 1627–1639.
67. [67] Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:2 (2015), 123–135.
68. [68] Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:26 (2015), 2509–2520.
69. [69] Budczies, J., Bockmayr, M., Denkert, C., Klauschen, F., Lennerz, J.K., Györffy, B., et al. Classical pathology and mutational load of breast cancer - integration of two worlds. J Pathol Clin Res 1:4 (2015), 225–238.
70. [70] Nanda, R., Chow, L.Q., Dees, E.C., Berger, R., Gupta, S., Geva, R., et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34:21 (2016), 2460–2467.
71. [71] Rugo, H.S., Delord, J.P., Im, S.A., Ott, P.A., Piha-Paul, S.A., Bedard, P.L., et al. Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res, 76(4 Suppl.), 2016, S5-07.
72. [72] Majewski, I.J., Nuciforo, P., Mittempergher, L., Bosma, A.J., Eidtmann, H., Holmes, E., et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol 33:12 (2015), 1334–1339.
73. [73] Stagg, J., Loi, S., Divisekera, U., Ngiow, S.F., Duret, H., Yagita, H., et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A 108:17 (2011), 7142–7147.
74. [74] Akbay, E.A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J.H., Christensen, C.L., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3:12 (2013), 1355–1363.
75. [75] D'Incecco, A., Andreozzi, M., Ludovini, V., Rossi, E., Capodanno, A., Landi, L., et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 112:1 (2015), 95–102.
76. [76] Parsa, A.T., Waldron, J.S., Panner, A., Crane, C.A., Parney, I.F., Barry, J.J., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13:1 (2007), 84–88.
77. [77] Balachandran, V.P., Cavnar, M.J., Zeng, S., Bamboat, Z.M., Ocuin, L.M., Obaid, H., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17:9 (2011), 1094–1100.
78. [78] Nik-Zainal, S., Alexandrov, L.B., Wedge, D.C., Van Loo, P., Greenman, C.D., Raine, K., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149:5 (2012), 979–993.
79. [79] Audeh, M.W., Dadmanesh, F., Yearley, J., Abstract P4-04-01: PDL-1 expression in primary breast cancers with germline mutations in BRCA 1 and 2. Cancer Research, 76(4 Suppl.), 2016 P4-04-01-P4-04-01.
80. [80] Castle, J.C., Kreiter, S., Diekmann, J., Lower, M., van de Roemer, N., de Graaf, J., et al. Exploiting the mutanome for tumor vaccination. Cancer Res 72:5 (2012), 1081–1091.
81. [81] Robbins, P.F., Lu, Y.C., El-Gamil, M., Li, Y.F., Gross, C., Gartner, J., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:6 (2013), 747–752.
82. [82] Wick, D.A., Webb, J.R., Nielsen, J.S., Martin, S.D., Kroeger, D.R., Milne, K., et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res 20:5 (2014), 1125–1134.
83. [83] van Rooij, N., van Buuren, M.M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31:32 (2013), e439–e442.
84. [84] Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:23 (2014), 2189–2199.
85. [85] Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:6230 (2015), 124–128.
86. [86] Brown, S.D., Warren, R.L., Gibb, E.A., Martin, S.D., Spinelli, J.J., Nelson, B.H., et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24:5 (2014), 743–750.
87. [87] Rajasagi, M., Shukla, S.A., Fritsch, E.F., Keskin, D.B., DeLuca, D., Carmona, E., et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 124:3 (2014), 453–462.
88. [88] McGranahan, N., Furness, A.J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:6280 (2016), 1463–1469.
89. [89] Segal, N.H., Parsons, D.W., Peggs, K.S., Velculescu, V., Kinzler, K.W., Vogelstein, B., et al. Epitope landscape in breast and colorectal cancer. Cancer Res 68:3 (2008), 889–892.
90. [90] Heemskerk, B., Kvistborg, P., Schumacher, T.N., The cancer antigenome. EMBO J 32:2 (2013), 194–203.
91. [91] van der Burg, S.H., Arens, R., Ossendorp, F., van Hall, T., Melief, C.J., Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16:4 (2016), 219–233.
92. [92] Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:9 (2007), 1050–1059.
93. [93] Demaria, S., Volm, M.D., Shapiro, R.L., Yee, H.T., Oratz, R., Formenti, S.C., et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7:10 (2001), 3025–3030.
94. [94] Ruffell, B., Au, A., Rugo, H.S., Esserman, L.J., Hwang, E.S., Coussens, L.M., Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 109:8 (2012), 2796–2801.
95. [95] Ma, Y., Adjemian, S., Mattarollo, S.R., Yamazaki, T., Aymeric, L., Yang, H., et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38:4 (2013), 729–741.
96. [96] Albert, M.L., Sauter, B., Bhardwaj, N., Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:6671 (1998), 86–89.
97. [97] Fonteneau, J.F., Larsson, M., Bhardwaj, N., Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. Curr Opin Immunol 14:4 (2002), 471–477.
98. [98] Loi, S., Dushyanthen, S., Beavis, P.A., Salgado, R., Denkert, C., Savas, P., et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 22:6 (2016), 1499–1509.
99. [99] US National Library of Medicine, ClinicalTrials.gov. 2016 https://clinicaltrials.gov/ct2/show/record/NCT02425891.
100. [100] Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:11 (2008), 1789–1796.
101. [101] Tamura, K., Shimizu, C., Hojo, T., Akashi-Tanaka, S., Kinoshita, T., Yonemori, K., et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 22:6 (2011), 1302–1307.
102. [102] Norton, N., Olson, R.M., Pegram, M., Tenner, K., Ballman, K.V., Clynes, R., et al. Association studies of Fcgamma receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunol Res 2:10 (2014), 962–969.
103. [103] Park, S., Jiang, Z., Mortenson, E.D., Deng, L., Radkevich-Brown, O., Yang, X., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18:2 (2010), 160–170.
104. [104] Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:17 (2004), 5650–5655.
105. [105] Muller, P., Kreuzaler, M., Khan, T., Thommen, D.S., Martin, K., Glatz, K., et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med, 7(315), 2015, 315ra188.
106. [106] US National Library of Medicine, ClinicalTrials.gov. 2016 https://clinicaltrials.gov/ct2/show/NCT02129556.
107. [107] US National Library of Medicine, ClinicalTrials.gov. 2015 https://clinicaltrials.gov/ct2/show/NCT02318901.
108. [108] US National Library of Medicine, ClinicalTrials.gov. 2016 https://clinicaltrials.gov/ct2/show/NCT02605915.
109. [109] Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:6230 (2015), 62–68.
110. [110] US National Library of Medicine, ClinicalTrials.gov. 2016 https://clinicaltrials.gov/ct2/show/NCT02348320.
111. [111] Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:10 (2009), 947–957.
112. [112] Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:26 (2011), 2507–2516.
113. [113] Catenacci, D.V., Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 9:5 (2015), 967–996.
114. [114] Barker, H.E., Paget, J.T., Khan, A.A., Harrington, K.J., The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15:7 (2015), 409–425.
115. [115] Filatenkov, A., Baker, J., Strober, S., Disruption of evasive immune cell microenvironment in tumors reflects immunity induced by radiation therapy. OncoImmunology, 5(2), 2016, e1072673.
116. [116] US National Library of Medicine, ClinicalTrials.gov. 2016 https://clinicaltrials.gov/ct2/show/NCT02318771.
117. [117] US National Library of Medicine, ClinicalTrials.gov. 2016 https://clinicaltrials.gov/ct2/show/NCT02303366.